Loading
A phase 3 trial of Vebreltinib run by Beijing Pearl Biotechnology Limited Liability Company in non-small-cell lung cancer and small-cell lung cancer, now recruiting.
A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2) is a phase 3 interventional study registered as NCT05989542 by Beijing Pearl Biotechnology Limited Liability Company, with 136 participants planned, started 2023-10-16. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Beijing Pearl Biotechnology Limited Liability Company, Vebreltinib, MET exon 14 and MET-amplified non-small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Beijing Pearl Biotechnology Limited Liability Company, Vebreltinib, Small-molecule kinase inhibitors.
Shares Vebreltinib, MET exon 14 and MET-amplified non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Vebreltinib, MET exon 14 and MET-amplified non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Beijing Pearl Biotechnology Limited Liability Company, Vebreltinib.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/